SCHEMBL6456041

SCHEMBL6456041

Cc1sc(C(=O)N(C)C)cc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.63
HPGD P15428 2/20 0.63
NPC1 O15118 1/20 0.63
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.41
PLK1 P53350 1/20 0.40
PLAU P00749 2/20 0.40
HSD17B1 P14061 2/20 0.40
HSD17B2 P37059 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
C1S P09871 1/20 0.40
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HTT P42858 1/20 0.38
DAO P14920 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797326 0.83 KDM4E (0.55) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL1801707 0.81 PLK1 (0.43) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL6454412 0.80 MAPK1 (0.52) PLK1PLAUC1SMAPK1
SCHEMBL6883034 0.77 PLK1 (0.65) SMN1; SMN2HPGDNPC1RAB9APLK1
SCHEMBL6018784 0.75 ALDH1A1 (0.52) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL6018804 0.74 PLK1 (0.38) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL5718225 0.73 MAPT (0.38) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL6455459 0.70 HDAC6 (0.57) SMN1; SMN2HPGDNPC1MEN1KMT2A
SCHEMBL6255667 0.70 ALDH1A1 (0.52) SMN1; SMN2MEN1KMT2AKDM4EMAPT
SCHEMBL3423443 0.69 ALDH1A1 (0.44) SMN1; SMN2PLAUHSD17B2C1SKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534700-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2005-06-01 EP claimed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US claimed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO claimed
EP-1394159-A1 New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them Warner-Lambert Company LLC (US) 2004-03-03 EP claimed
EP-1534700-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2005-06-01 EP disclosed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO disclosed
EP-1394159-A1 New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them Warner-Lambert Company LLC (US) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 SMN1; SMN2 3494/4885HPGD 612/4885NPC1 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.